TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03031197

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tailored realtime triggered reminder pkg
Description: Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence.
Study: NCT04493073

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectulectomy
Description: decrease IOP

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trabectulectomy
Description: decrease IOP

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin
Description: Decrease bleb failure
Study: NCT04655131

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein isolate
Description: Commercially available, FDA approved whey protein isolate for dietary supplementation
Study: NCT04290117

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance and Commitment Training
Description: During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training
Description: During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Training
Description: During the ACT-based intervention, participants will get 4 training sessions in groups, once a week for an hour. Additionally, participants will be asked to implement behavioural exercises such as mindfulness and value-based exercises into their daily schedule.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene and bright light in the morning
Description: During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene and bright light in the morning
Description: During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Hygiene and bright light in the morning
Description: During the chronobiological intervention, participants will get 4 training sessions in groups, one hour per week. Additionally, they will use a daylight lamp at home, for 30 minutes per day after waking up.
Study: NCT03582410

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacral colpopexy with absorbable suture
Description: laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with absorbable suture

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sacral colpopexy with non absorbable suture
Description: laparoscopic sacral colpopexy to correct pelvic organ prolapse with anterior and posterior meshes with non absorbable suture
Study: NCT00971022

Intervention type: BEHAVIORAL
Intervention: Survey
Description: 20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.

Intervention type: BEHAVIORAL
Intervention: Focus Group
Description: 5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
Study: NCT04074577

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard technique First
Description: colonoscopy without automated polyp detection software

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: combination technique First
Description: automated polyp detection software
Study: NCT04533659

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ADA-based nutrition education with digital self-monitoring
Description: Diabetes nutrition education developed by the American Diabetes Association with digital self-monitoring for diet and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Nutrition (PBN) intervention group
Description: Personalized behavioral nutrition intervention consisting of digital self-monitoring for diet and physical activity, personalized nutrition change goal and recommendation, and diabetes nutrition education developed by ADA
Study: NCT02705937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dairy product
Description: Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aequasyal mouth spray
Description: The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
Study: NCT03046628

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Green laser (at 532nm) and a fast camera
Study: NCT02705183

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Multifractionated post-operative radiotherapy, several weeks after surgery
Study: NCT03624166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: patients will receive sub- anesthetic dose of ketamine 0.5 mg/kg in 3 ml of isotonic saline after spinal anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic saline
Description: patients will receive 3 ml of isotonic saline after spinal anesthesia
Study: NCT04488783

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc and ascorbate
Description: oral zinc and ascorbate
Study: NCT01852526

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental: hybrid system
Description: The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
Study: NCT01100996

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control enteral nutrition
Description: This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: enriched enteral feeding
Description: This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
Study: NCT01774344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (Stivarga, BAY73-4506)
Description: Regorafenib, 40 mg tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets matching in appearance
Study: NCT01852526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: hybrid system
Description: The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Plif
Description: monosegmental PLIF

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active Comparator: Plif
Description: monosegmental PLIF
Study: NCT01763281

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRH

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01374776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous iron carboxymaltose
Description: The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
Study: NCT03555084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extension of Virto B-Titanium
Description: In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virto B-Titanium
Description: In ear Hearing aid device individually modeled to ear canal geometry to compensate an individual Hearing loss.
Study: NCT00941954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured Education
Description: The intervention group will be offered a group-based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self-efficacy, barriers to physical activity and self-regulatory skills based on pedometer use. The programme will employ a person-centred approach to patient education that is based on self-management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5-10 participants by two trained educators and is 3.5 hours long. Brief follow-up counselling will be offered once every 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Written Information
Description: Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
Study: NCT01185145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast Brachytherapy with Mammosite RTS
Description: Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
Study: NCT00361283

Intervention type: DRUG
Group type: OTHER
Intervention: Atorvastatin
Description: atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
Study: NCT01185145

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy
Description: Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
Study: NCT03365427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: APP
Description: An APP designed for patients experienced TKA, including on-line lessons on the action, frequency, intensity of rehabilitation exercises, and reporting system monitored by stuff from surgery team.
Study: NCT00997386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan, and melphalan, and alemtuzumab
Description: intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).~intravenous melphalan 100 mg/m2 on day -3.~intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1.
Study: NCT04077632

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS: 20 minutes, 2mA, primary motor cortex anode (contralateral to the lesion) and supraorbital cathode (ipsilateral to the lesion).Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively.
Study: NCT03958734

Intervention type: OTHER
Group type: OTHER
Intervention: High-fat meal
Description: Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes

Intervention type: OTHER
Group type: OTHER
Intervention: High-fat meal
Description: Participants will be given a serving of Marie Callendar's Chocolate Satin Pie to eat over a period of 20 minutes
Study: NCT02781766

Intervention type: OTHER
Group type: OTHER
Intervention: Thrombin generation measurement.
Study: NCT04116203

Intervention type: DRUG
Group type: OTHER
Intervention: Metformin
Description: Manufacturer's standard 500 mg. Submission Control No.:128147

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Fish Oil and Metformin
Description: Combo of 2 other arms

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Fish Oil
Description: NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral
Study: NCT01872026

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP7991
Description: oral
Study: NCT02792374

Intervention type: OTHER
Intervention: Psychological Measurement
Description: Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale

Intervention type: OTHER
Intervention: Psychological Measurement
Description: Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
Study: NCT04139538

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthodontic treatment
Description: Malocclusion will be treated with orthodontic appliances (fixed or removable)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: orthodontic treatment
Description: Malocclusion will be treated with orthodontic appliances (fixed or removable)
Study: NCT06027372

Intervention type: DEVICE
Intervention: LARGAN ECG Holter
Description: wear LARGAN ECG Holter during sleep once after completion of pulmonary function test

Intervention type: DEVICE
Intervention: LARGAN ECG Holter
Description: wear LARGAN ECG Holter during sleep once after completion of pulmonary function test
Study: NCT00777816

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XOMA 052
Description: A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
Study: NCT02747602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC-1204
Description: 40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
Study: NCT00624858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naltrexone SR 32 mg/ bupropion SR 360 mg daily
Description: All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.~During the study, subjects will receive ancillary therapy including advice on diet and exercise
Study: NCT03499756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-based interpersonal psychotherapy
Description: The contents include: (1) an overview of changes associated with the role transition of parenthood and an introduction to the coping skills relating to role transition and parenting; (2) discussing common postpartum and interpersonal difficulties, such as conflicts with partners or extended family, and teaching effective communication skills to resolve interpersonal conflicts and maintain a good interpersonal relationship; and (3) building family strengths and resources by enhancing family sense of coherence, such as reassessing the challenges of the new role, applying problem solving techniques to deal with role transition and interpersonal problems, and developing new social support.
Study: NCT02194413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic touch
Description: receiving healing touch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00544206

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard enteral feeding product
Description: 16 hrs daily x 5 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes specific feeding product
Description: 16 hrs daily for 5 days
Study: NCT01777867

Intervention type: PROCEDURE
Intervention: Cough Reflex Sensitivity
Description: Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.

Intervention type: PROCEDURE
Intervention: Cough Reflex Sensitivity
Description: Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.

Intervention type: PROCEDURE
Intervention: Cough Reflex Sensitivity
Description: Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.

Intervention type: PROCEDURE
Intervention: Methacholine Challenge
Description: A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.

Intervention type: PROCEDURE
Intervention: Methacholine Challenge
Description: A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.

Intervention type: PROCEDURE
Intervention: Methacholine Challenge
Description: A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
Study: NCT04493073

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ologen Collagen Implant
Description: Ologen Collagen Implant (Aeon Astron Europe, Netherlands)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mitomycin-C Kyowa®
Description: Mitomycin-C Kyowa® (Biochem Pharmaceutical Industries, India)
Study: NCT03820141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: programmed cell death-ligand 1 inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: anti-HER2 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: anti-HER2 monoclonal antibody
Study: NCT02015754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DEBIRI
Description: Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LC Bead M1
Description: The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE a minimally invasive procedure performed to restrict a tumor's blood supply.